MET amplification is diagnosed in 5-22 % of EGFR-mutated NSCLC patients with acquired resistance to EGFR-TKIs (Michelotti et al., 2022[58]; Zhang et al., 2019[99]). This evidence concerns the gene MET and non-small cell lung carcinoma.